Effectiveness of Intragastric Balloon Treatment for Obese Patients: One-Year Follow-up After Balloon Removal
- 652 Downloads
The Bioenterics Intragastric Balloon (BIB) is effective for weight loss. However, comparisons of its effectiveness between groups with different body mass index (BMI) are rare. This study compared the effectiveness of BIB treatment in patients with BMI <32 kg/m2 and those with BMI ≧32 kg/m2 at the time of BIB removal and at 1 year later.
Between April 2009 and June 2011, 28 obese patients who completed a full course of BIB treatment were enrolled. There are 16 patients with BMI <32 and 12 with BMI ≧32. Patients who lost more than 20 % of excess weight (% EWL) were categorized as responders.
The BMI significantly fell from 32.4 ± 3.7 to 28.5 ± 3.7 kg/m2 (P < 0.01) at the time of BIB removal. All biochemical measurements except for cholesterol level were significantly improved. The median value of %EWL of all patients at BIB removal was 40.1, and 20 patients (71.4 %) were responders. Adherence to dietitian counseling was significantly better in responders than in non-responders (85 vs. 25 %, respectively; P < 0.01). The percentage of responders at 1 year after BIB removal was significantly higher among patients with BMI <32 than those with ≧32 (62.5 vs. 16.7 %, respectively; P = 0.02).
BIB placement can achieve significant weight loss and improvement of co-morbidities in obese patients. Better adherence to dietitian counseling is associated with better response. Patients with BMI <32 maintain better weight loss at 1 year after BIB removal.
KeywordsWeight loss Gastric balloon Body mass index Obesity
BioEnterics Intragastric Balloon
Body mass index
classification Los Angeles classification
Excess weight loss
This study was supported by a Project of the E-Da Hospital, Grant Number EDAHP101017.
Conflict of Interest
All contributing authors declare that they have no conflicts of interest.
- 9.Ganesh R, Rao AD, Baladas HG, et al. The Bioenteric Intragastric Balloon (BIB) as a treatment for obesity: poor results in Asian patients. Singap Med J. 2007;48:227–31.Google Scholar
- 12.Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–5.PubMedCrossRefGoogle Scholar